United States Pharmaceuticals

HOOKIPA Pharma Inc (HOOK)

Track

Recent insider trading activity at HOOKIPA Pharma Inc. has been characterized by sales from executive leadership. The most recent transactions occurred on August 19, 2025, involving the Chief Executive Officer. These sales follow similar divestment activity by the CEO and CFO in July 2025, representing the primary insider movements observed in the last three months.
Ticker: HOOK Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for HOOKIPA Pharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 19 Aug 2025
Value US$3,243,451.14 | Price 337.50 | Shares 92,695 (+35.7%)
Proposed sale 19 Aug 2025
Value US$240,017.71 | Price 202.55 | Shares 21,348
Proposed sale 19 Aug 2025
Value US$20,155.00 | Price 0.80 | Shares 25,172
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-09 2025-08-19 S Sale
2.4
Peters Malte

Chief Executive Officer

Executive Director
92,695 +35.7%
337.50
US$3,243,451 		92,695 +35.7% 337.50 US$3,243,451
2025-08-27 2025-08-19 PrS Proposed sale
2.4
Peters Malte

Officer

Officer
21,348
202.55
US$240,018 		21,348 202.55 US$240,018
2025-08-27 2025-08-19 PrS Proposed sale
2.4
Peters Malte

Officer

Officer
24,491
90.81
US$3,102,020 		24,491 90.81 US$3,102,020
2025-07-23 2025-07-22 S Sale
2.4
Peters Malte

Chief Executive Officer

Executive Director
29,176 -26.8%
0.92
US$26,842 		29,176 -26.8% 0.92 US$26,842
2025-07-23 2025-07-22 S Sale
3.8
Coelho Mary Theresa

EVP and CFO

Executive Director
13,609 -19.5%
0.92
US$12,520 		13,609 -19.5% 0.92 US$12,520
2023-08-22 2023-08-21 B Purchase
1.0
Kandera Reinhard

Chief Financial Officer

Executive Director
7,000 +19.4%
0.73
US$5,075 		7,000 +19.4% 0.73 US$5,075
2023-08-17 2023-08-16 B Purchase
1.0
Kandera Reinhard

Chief Financial Officer

Executive Director
8,000 +28.5%
0.71
US$5,712 		8,000 +28.5% 0.71 US$5,712
2023-07-11 2023-07-11 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +7.5%
0.83
US$4,142 		5,000 +7.5% 0.83 US$4,142
2023-07-11 2023-07-07 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +8.1%
0.81
US$4,050 		5,000 +8.1% 0.81 US$4,050
2023-07-07 2023-07-05 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +8.8%
0.89
US$4,450 		5,000 +8.8% 0.89 US$4,450
2023-07-05 2023-07-03 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +9.6%
0.89
US$4,456 		5,000 +9.6% 0.89 US$4,456
2023-07-03 2023-06-30 B Purchase
1.0
Kandera Reinhard

Chief Financial Officer

Executive Director
12,000 +74.6%
0.88
US$10,560 		12,000 +74.6% 0.88 US$10,560
2022-01-12 2021-12-21 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
2,205 -2.5%
2.49
US$5,490 		2,205 -2.5% 2.49 US$5,490
2022-01-12 2021-12-21 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
7,440 -8.1%
2.49
US$18,526 		7,440 -8.1% 2.49 US$18,526
2022-01-12 2021-12-21 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
5,304 -6.2%
2.49
US$13,207 		5,304 -6.2% 2.49 US$13,207
2021-04-23 2021-04-21 S Sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
328,620 -9.4%
11.60
US$3,812,386 		328,620 -9.4% 11.60 US$3,812,386
2021-03-29 2021-03-25 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
28,546 -0.8%
13.12
US$374,569 		28,546 -0.8% 13.12 US$374,569
2021-03-26 2021-03-24 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
52,690 -1.4%
13.70
US$721,616 		52,690 -1.4% 13.70 US$721,616
2021-03-25 2021-03-23 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
40,000 -1.1%
13.91
US$556,476 		40,000 -1.1% 13.91 US$556,476
2021-03-24 2021-03-22 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
40,534 -1.1%
14.54
US$589,263 		40,534 -1.1% 14.54 US$589,263
2021-03-23 2021-03-19 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
166,230 -4.3%
14.60
US$2,427,739 		166,230 -4.3% 14.60 US$2,427,739
2020-12-18 2020-12-17 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
16,478 -17.6%
11.76
US$193,781 		16,478 -17.6% 11.76 US$193,781
2020-12-18 2020-12-17 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
11,501 -15.2%
11.70
US$134,562 		11,501 -15.2% 11.70 US$134,562
2020-12-18 2020-12-16 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
380 -0.7%
11.70
US$4,446 		380 -0.7% 11.70 US$4,446
2020-10-06 2020-10-02 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
300 -0.0%
10.00
US$3,000 		300 -0.0% 10.00 US$3,000
2020-09-17 2020-09-15 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
9,261 -0.2%
13.16
US$121,913 		9,261 -0.2% 13.16 US$121,913
2020-09-17 2020-09-15 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
32,336 -0.8%
12.45
US$402,564 		32,336 -0.8% 12.45 US$402,564
2020-07-22 2020-07-20 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
12,483 -0.3%
11.94
US$149,102 		12,483 -0.3% 11.94 US$149,102
2020-07-22 2020-06-29 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
3,280 -0.1%
11.78
US$38,628 		3,280 -0.1% 11.78 US$38,628
2020-07-01 2020-06-29 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
3,280 -0.1%
11.78
US$38,628 		3,280 -0.1% 11.78 US$38,628
2020-01-31 2020-01-29 S Sale
2.6
Matushansky Igor

Chief Medical Officer
5,500 -9.3%
12.73
US$69,992 		5,500 -9.3% 12.73 US$69,992
2020-01-27 2020-01-23 S Sale
3.1
Lilja Anders

Sr. VP, Technical Development
7,568 -100.0%
12.81
US$96,932 		7,568 -100.0% 12.81 US$96,932
2020-01-27 2020-01-23 S Sale
3.1
Lilja Anders

Sr. VP, Technical Development
4,075 -100.0%
12.17
US$49,601 		4,075 -100.0% 12.17 US$49,601
2020-01-21 2020-01-21 S Sale
2.9
Orlinger Klaus

Sr. VP, Research
6,789 -100.0%
12.02
US$81,592 		6,789 -100.0% 12.02 US$81,592
2020-01-21 2020-01-16 S Sale
2.9
Orlinger Klaus

Sr. VP, Research
1,711 -100.0%
11.56
US$19,781 		1,711 -100.0% 11.56 US$19,781
2020-01-16 2020-01-14 S Sale
2.9
Orlinger Klaus

Sr. VP, Research
8,500 -100.0%
11.30
US$96,053 		8,500 -100.0% 11.30 US$96,053
2019-12-23 2019-12-19 S Sale Matushansky Igor

Chief Medical Officer

Officer
10,404 -15.0%
9.93
US$103,312 		10,404 -15.0% 9.93 US$103,312
2019-12-19 2019-12-17 S Sale Matushansky Igor

Chief Medical Officer

Officer
11,484 -20.9%
7.87
US$90,379 		11,484 -20.9% 7.87 US$90,379
2019-04-25 2019-04-23 B Purchase
0.5
Forbion Capital Fund II Cooperatief U.A.
Large shareholder
53,571 +2.2%
14.00
US$749,994 		53,571 +2.2% 14.00 US$749,994
2019-04-25 2019-04-23 B Purchase
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
357,142 +9.9%
14.00
US$4,999,988 		357,142 +9.9% 14.00 US$4,999,988
2019-04-23 2019-04-23 B Purchase
3.3
BAKER BROS. ADVISORS LP

Former 10% owner
820,729 +inf%
14.00
US$11,490,206 		820,729 +inf% 14.00 US$11,490,206
2019-04-23 2019-04-23 B Purchase
3.3
BAKER BROS. ADVISORS LP

Former 10% owner
72,128 +inf%
14.00
US$1,009,792 		72,128 +inf% 14.00 US$1,009,792
Explore more

More insider trading research around HOOKIPA Pharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America